
About Us
Based in Parma, Italy, Chiesi is an international research-focused biopharmaceutical group with 90 years’ experience, operating in 31 countries. More than 8,000 employees across the group are united by a singular purpose: promoting a healthier world for our people, patients, and the planet. This is what drives us as we research, develop, and market innovative drugs across our main therapeutic areas. Discover more here.
At Chiesi we are thinking generations ahead, driving sustainable innovation with purpose. This fosters a culture of reliability, transparency, and ethical behaviour at every level. As a Benefit Corporation and a certified B Corp, we have embedded sustainability in our bylaws and continuously measure our impact.
Diversity, inclusion, and equal opportunity are at the heart of who we are. We believe our differences make us stronger. We are a vibrant ecosystem of passionate, talented individuals united by strong values, each bringing unique perspectives that help us to continuously challenge the status quo for the better.
Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a Chiesi Group’s business unit established in February 2020 and focused on research, development and commercialization of treatments and patient support services for rare and ultra-rare disorders, many of whom have limited or no treatments available.
This unit is based in Boston, Massachusetts, with a strong synergy with the headquarters in Parma.
Rare unit has a focus on research and product development for lysosomal storage diseases, rare hematology, ophthalmology disorders and rare immunodeficiencies. The unit is also a dedicated partner with global leaders in scientific research, patient advocacy and care. Discover more here
Who we are looking for
The Lead, Gross-To-Net (GTN), Global Rare Diseases is responsible for the integrity and strategic direction of GTN forecasting, reporting and management of accrued financial reserves in US. This high impact role will also be responsible for the development and implementation of strategic, cross-functional business cases, ensuring alignment with global commercialization strategies for the full Chiesi GRD portfolio (8-10 reimbursed products).
Reporting to the VP of Market Access for the Americas, this role will be the subject matter expert for GTN modeling, scenario planning, and forecasting in partnership with FP&A, Market Access, Patient Services and Government Pricing. You will undertake various modelling and scenario planning analyses to drive financial accuracy in alignment with FP&A cycles for budgeting and forecasting. This role is critical to integrating the dynamics of the marketplace and government policies into financial performance.
As a leader within the Market Access team, you will also assist in building commercial payer business cases related to the optimization of our contracting strategy through the formulation of insights and assumptions for the GRD portfolio. This will require an extensive knowledge of Chiesi’s HUB services, trade & distribution strategy, and the reimbursement landscape for various therapeutics areas.
This is a strategic and management role leveraging your understanding of the global and US health care systems, competitive insights, and clinical understanding, to determine opportunities where we can drive value for Chiesi and our patients.
Hybrid position based in Boston, MA office. #LI-Hybrid
The annual base pay for this position ranges from $181,140 to $225,060. Hourly and salaried non-exempt employees will also be paid overtime pay when working qualifying overtime hours. Base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience. If hired, the employee will be in an “at-will position” and the Company reserves the right to modify base pay (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors.

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care.
The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with more than 30 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com